Company intelligence / Profile preview

Telerate

Paris, France

Ownership: Private
Development stage: Other

Overview

Stellate Therapeutics is a biotechnology company focused on developing microbiome-derived small molecules for the treatment of neurodegenerative diseases. The company's platform leverages the human gut-brain axis to identify and develop first-in-class therapies that target the underlying pathology of disorders such as Parkinson's and Alzheimer's disease. Its lead candidate, STL-101, is a microbiome-derived molecule being developed for neuroprotection in Parkinson's disease. Stellate operates with a virtual research model and maintains offices in Paris and New York.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

eureKARE

Beyond the preview

Go deeper on Telerate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Telerate.

Explore the full profile